Disruption of the PHRF1 Tumor Suppressor Network by PML-RARα Drives Acute Promyelocytic Leukemia Pathogenesis
Related Experiment Video
Updated: Apr 17, 2026
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Céline Prunier1, Ming-Zhu Zhang2, Santosh Kumar3
1Laboratory of Cell Signaling and Carcinogenesis, INSERM UMRS938, 184 Rue du Faubourg St-Antoine, 75571 Paris, France.
Abstract:
PHRF1 functions as an essential component of the TGF-β tumor suppressor pathway by triggering degradation of the homeodomain repressor factor TGIF. This leads to redistribution of cPML into the cytoplasm, where it coordinates phosphorylation and activation of Smad2 by the TGF-β receptor. In acute promyelocytic leukemia (APL), acquisition of PML-RARα is known to impede critical aspects of TGF-β signaling, including myeloid differentiation. Although these defects are thought to rely on suppression of cPML activity, the mechanisms underlying this phenomenon remain enigmatic. Here, we find that an abnormal function of PML-RARα is to interfere with TGIF breakdown, presumably by competing with PHRF1 for binding to TGIF, culminating in cPML sequestration and inactivation. Enforcing PHRF1 activity is sufficient to restore TGF-β cytostatic signaling in human blasts and suppress APL formation in a mouse model of APL, providing proof-of-concept data that suppression of PHRF1 activity by PML-RARα represents a critical determinant in APL pathogenesis.
Insights
PHRF1 protein degradation of TGIF is crucial for TGF-β tumor suppression. In acute promyelocytic leukemia (APL), PML-RARα blocks this process, leading to disease progression.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Signaling
Background:
- The TGF-β pathway is a critical tumor suppressor mechanism.
- PHRF1 (Polycomb repressive complex 1-interacting protein) is key in this pathway.
- Acute promyelocytic leukemia (APL) involves impaired TGF-β signaling and myeloid differentiation.
Purpose of the Study:
- To elucidate the mechanism by which PML-RARα disrupts TGF-β signaling in APL.
- To investigate the role of PHRF1 and TGIF in APL pathogenesis.
- To explore therapeutic strategies targeting PHRF1 activity.
Main Methods:
- Investigated protein-protein interactions between PHRF1, TGIF, and PML-RARα.
- Assessed TGF-β pathway activation and Smad2 phosphorylation.
- Utilized cell culture models of human APL blasts.
- Employed a mouse model for APL formation and treatment.
Main Results:
- PML-RARα interferes with PHRF1-mediated TGIF degradation.
- This interference sequesters and inactivates cytoplasmic PML (cPML).
- Restoring PHRF1 activity re-establishes TGF-β signaling and suppresses APL in vivo.
Conclusions:
- PML-RARα's suppression of PHRF1 activity is a critical driver of APL.
- Targeting PHRF1 offers a potential therapeutic strategy for APL.
- Understanding this mechanism provides insights into TGF-β pathway regulation in cancer.
